Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2019

View Archived Issues

Patient enrollment ongoing in phase II study of KPL-716 in subjects with prurigo nodularis

iTeos Therapeutics initiates first-in-human study of EOS-100850

KCNQ1 gene mutation tied to gingival fibromatosis and growth hormone deficiency

High-fructose corn syrup deals low blow to intestines

Keeping a tight BBB after stroke

Eukaryotic initiation factor 2B modulators discovered at Denali Therapeutics

RaQualia Pharma, XuanZhu Pharma patent sodium channel protein type 9 subunit alpha blockers

Mavupharma identifies new E-NPP 1 inhibitors

Corvus Pharmaceuticals discloses new adenosine A2A and A2B receptor antagonists

LCN2 predicts organ failure and mortality risk in surgical patients with infection

Aska Pharmaceutical discovers MPGES-1 inhibitors

Macrophages regulate metabolism via noninflammatory factors

ABCG2 and GREM2 found to be associated with response to allopurinol

New mutations in NPHP3 and NEK8 are associated with renal-hepatic-pancreatic dysplasia

FDA grants IND allowance for Aptose to initiate phase I study of CG-806

Vascepa associated with reduced total ischemic events in REDUCE-IT

Data presented from first study of phase III program of AVP-786 for agitation in Alzheimer's

Smyraf approved in Japan to treat rheumatoid arthritis

European phase III ARTEMIS study of AR-101 meets primary endpoint

Phase II trial of lurbinectedin in relapsed SCLC meets primary endpoint

Vaccibody reports phase IIa data on VB10.16 immunotherapy for CIN 2/3

Transgene and BioInvent extend multifunctional oncolytic virus collaboration

AQP5 gene polymorphism prolongs survival of patients with sepsis

Japanese MHLW approves Kymriah and related therapies Treakisym and Actemra

Knockout model highlights role of RasD2 in metabolism

Japan first to approve Skyrizi for psoriasis indications

Vyndaqel approved in Japan for transthyretin amyloid cardiomyopathy

Onoact gains approval in Japan for refractory and urgent fatal arrhythmia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...